When Intervention Stifles Innovation

When Intervention Stifles Innovation

Dr. Gregory Dolin of the Center for Medicine and Law at the University of Baltimore School of Law shared his objections to legislative proposals that falsely link drug costs with patents in an op-ed that ran in The Washington Times this week.

As Dolin states, current legislative proposals would allow excessive regulatory authority into the free market:

“…the government would be given the power not to “negotiate,” but to force drug manufacturers to accept a price that budget-conscious bureaucrats deem “fair.” If the government could in this way take valuable inventions from its owners in order to save money, patents would essentially become worthless.”

Read the full op-ed

 

Filed under: Inside BIO Industry Analysis, Patently BIOtech, , ,